Gilead research report:
Gilead Sciences: The HIV Cash Machine Quietly Buying Its Way Into CAR-T's Next Generation
- 1. The Thesis
- 2. Two Engines: Defend HIV, Attack Oncology
- 3. The Financial Paradox: Why A "Loss" Quarter Was Actually A Great Quarter
- 4. The HIV Franchise: Cannibalizing Itself On Purpose
- 5. PrEP Crosses $1 Billion In A Quarter
- 6. The CAR-T Story: Why Anito-cel Matters
- 7. Trodelvy: The Other Growth Engine
- 8. The Rest Of The 2026 Shopping Cart
- 9. Moat Versus Risk, In Gilead's Own Words
- 10. The Road To 2028
- 11. The Price: A Dividend-Paying Defensive Name At A Reasonable Multiple
- 12. What Could Go Wrong
- 13. Muffett's Take
1 The Thesis
Gilead has spent most of the last two decades known for one thing: HIV. Biktarvy is the regimen of choice for the majority of newly diagnosed and switching patients in the U.S., and that single franchise still throws off cash at an 87% gross margin. What's changed, and what this note is really about, is what Gilead has started doing with that cash. In the second quarter of 2026 alone, the company deployed $13 billion into acquiring Arcellx, Tubulis, and Ouro Medicines — a deliberate, well-funded push to build a second growth engine in oncology and immunology before the HIV franchise's eventual patent cliff arrives. The centerpiece of that push, and the part you specifically asked about, is cell therapy: Gilead already owns Kite Pharma's Yescarta and Tecartus CAR-T franchise, both of which have been losing share to newer in-class competition, and it just spent $7.8 billion to acquire the company behind what it's betting is the next-generation answer.
2 Two Engines: Defend HIV, Attack Oncology
This is as clean a statement of corporate strategy as you'll find in any biopharma investor deck: one engine defends a dominant, extraordinarily profitable existing franchise, and the cash it throws off directly funds a second engine attacking new disease areas before the first one inevitably declines. It's not a subtle rotation — it's an explicit, quantified capital allocation plan, and the fact that management is willing to say "eventual HIV patent cliffs" out loud in its own materials is a level of honesty about long-term risk that we appreciate seeing from a company this size.
3 The Financial Paradox: Why A "Loss" Quarter Was Actually A Great Quarter
Here's the number that generated the alarming headlines: Gilead reported a quarterly net loss and adjusted EPS of negative $6.75 against a consensus expectation of positive $7.25. Here's the context those headlines mostly skipped: that entire swing is explained by an $11.2 billion acquired in-process R&D charge tied to closing the Arcellx, Tubulis, and Ouro Medicines deals in the same quarter — a mandatory, non-cash accounting treatment for acquired pipeline assets, not evidence the underlying business struggled. Strip that charge out and the base business generated $2.27 per share of adjusted earnings, up on a base of 10% revenue growth, with underlying first-half 2026 earnings growth of 13%. Reported Q2 product sales still rose 8% and beat Wall Street's revenue estimate outright. This is a business that had a genuinely strong quarter wearing an accounting result that looked like a bad one.
4 The HIV Franchise: Cannibalizing Itself On Purpose
The strategic insight on this slide is the single most important structural point in the whole HIV story: Gilead is racing to obsolete its own products before a competitor does it for them. Biktarvy, secure on patent through 2033, remains the daily-dosing anchor. BIC/LEN, awaiting an FDA decision in late August 2026, is a next-generation once-daily switch option. And ISL/LEN, developed jointly with Merck, is a once-weekly oral regimen already through positive Phase 3 data and targeting a 2027 launch. Each successive product cannibalizes some of the one before it — and that's precisely the point. A patient base that keeps upgrading to Gilead's own newer regimen never has a reason to go looking at a competitor's.
This chart is worth sitting with because it names the one weak spot honestly rather than hiding it: cell therapy — Yescarta and Tecartus — fell 14% year over year to $417 million, explicitly attributed to in-class competition. That's the exact problem the Arcellx acquisition and anito-cel are meant to solve, and we'll get to that directly in a moment. Everything else in this chart moved the right direction: HIV up 12% to $5.69 billion, Trodelvy up 26%, and liver disease up 10% with Livdelzi's revenue doubling year over year.
5 PrEP Crosses $1 Billion In A Quarter
Prevention has quietly become one of Gilead's best-performing businesses. Descovy grew 60% year over year to $801 million in the quarter, and Yeztugo — the twice-yearly injectable form of lenacapavir — grew 40% sequentially to $232 million on the back of a genuinely remarkable clinical profile: greater than 99.9% efficacy and a persistency rate above 70% at six months, meaningfully higher than what daily oral regimens typically achieve given real-world adherence challenges. Combined, the PrEP business crossed $1 billion in quarterly revenue for the first time in company history, running at a $4 billion annual pace against a total addressable market Gilead sizes at $20 billion — meaning even sustained execution from here still leaves most of the market unclaimed.
6 The CAR-T Story: Why Anito-cel Matters
This is the section you specifically asked for, and it's worth doing properly. Kite Pharma, Gilead's cell-therapy subsidiary, has long been one of the two dominant names in commercial CAR-T alongside Bristol Myers Squibb, with Yescarta approved across several lymphoma indications and Tecartus in mantle cell lymphoma and adult ALL. But the chart above doesn't lie: that franchise fell 14% in the most recent quarter, squeezed by newer in-class competitors — most notably Johnson & Johnson and Legend Biotech's Carvykti in multiple myeloma, a fight Gilead was not originally positioned to win with its existing lymphoma-focused portfolio.
Gilead's answer, acquired outright for $7.8 billion in February 2026 and folded into Kite ahead of schedule, is anito-cel — a BCMA-directed CAR-T therapy built around Arcellx's proprietary D-Domain binder platform rather than the legacy viral-vector approach underlying Yescarta and Tecartus. The engineering pitch is specific and credible: a smaller, more targeted binder that sidesteps some of the manufacturing complexity of older-generation CAR-T constructs, resulting in a reported 98% first-pass manufacturing success rate and an 18-day global median turnaround from a patient's cell collection to receiving their therapy — materially faster than the manufacturing timelines that have historically been one of CAR-T's biggest practical drawbacks. Clinically, the iMMagine-1 trial reported a 96% overall response rate and a 74% complete response rate in heavily pretreated multiple myeloma patients, a genuinely strong result in a hard-to-treat population.
The FDA accepted anito-cel's biologics license application for fourth-line-plus relapsed/refractory multiple myeloma with a PDUFA target date of December 23, 2026 — a firm, near-term catalyst rather than a vague future pipeline hope. The deal structure itself signals confidence without overpaying for a guarantee: Arcellx shareholders received $115 per share in cash plus a contingent value right worth up to $5 more per share, payable only if cumulative global anito-cel sales reach at least $6 billion through the end of 2029. That's Gilead putting real money down while still tying a meaningful slice of the purchase price to actual commercial performance — a disciplined structure for what is effectively a bet on relaunching Gilead's entire cell-therapy franchise into a $20 billion multiple myeloma market where J&J's Carvykti currently sets the competitive bar.
7 Trodelvy: The Other Growth Engine
While cell therapy gets rebuilt, Trodelvy is already doing the growth-engine job Gilead's oncology pivot needs. Its move into first-line metastatic triple-negative breast cancer roughly doubles its addressable patient population relative to the second-line setting it was previously confined to, and NCCN Category 1 guideline status — the highest tier of clinical guideline endorsement — cements it as standard of care rather than a later-line alternative. A CHMP recommendation for Trodelvy plus Merck's Keytruda in first-line PD-(L)1-positive mTNBC in late July 2026 adds further momentum toward European approval on top of the U.S. clearance already secured.
8 The Rest Of The 2026 Shopping Cart
Arcellx gets the headline because of the CAR-T angle, but it's one of three deals in the same quarter, and the other two round out a genuinely diversified pipeline bet: Tubulis brings next-generation antibody-drug conjugate technology with a novel linker-payload platform already showing a 61% response rate in early-stage ovarian cancer data, explicitly positioned to extend Gilead's ADC franchise beyond Trodelvy rather than duplicate it. Ouro Medicines brings bispecific T-cell engager technology and pivots existing oncology expertise into autoimmune disease — a genuinely different therapeutic direction that broadens the platform rather than just adding another cancer asset. Three deals, three distinct modalities, one clear organizing principle: build durable, differentiated growth outside HIV before the patent clock runs out.
9 Moat Versus Risk, In Gilead's Own Words
We appreciate a company willing to put its own concentration risk in writing: Biktarvy alone accounts for roughly 49% of total Gilead revenue, and that single product is now exposed to Medicare drug price negotiation under the Inflation Reduction Act as its eligibility window approaches — a real, quantifiable policy risk rather than a vague regulatory worry. ACA and Medicaid pricing shifts already caused a minor HIV market slowdown in the most recent quarter, evidence this risk isn't purely theoretical. None of this breaks the thesis, but it's the honest counterweight to a very entrenched moat, and it's a big part of why the oncology diversification push matters as much as it does.
10 The Road To 2028
What we like about this catalyst path is the density of near-term, binary events rather than a pipeline that's all promise five-plus years out. A regulatory decision roughly every few months from now through 2027 gives the market repeated, concrete opportunities to re-rate the stock on actual data and approvals rather than waiting years for the story to prove itself.
11 The Price: A Dividend-Paying Defensive Name At A Reasonable Multiple
GILD trades at $145.13, within its 52-week range of $108.46 to $157.29 — roughly 8% below its high, not a dramatic drawdown, but also not a stock the market has bid up ahead of its own fundamentals. Market cap is $179.95 billion. The trailing P/E is not meaningful given the GAAP loss described above, but the forward P/E of 16.2 times is genuinely reasonable for a company generating high-80s percent gross margins, growing its base business at double digits, and paying a real, growing dividend — currently yielding 2.26%, backed by ten consecutive years of dividend increases and roughly half of first-half 2026 free cash flow returned directly to shareholders. Beta of 0.34 confirms what the numbers already suggest: this is one of the more defensive, lower-volatility names available anywhere in this research library.
Analyst opinion is a genuine mix rather than uniform enthusiasm, which is worth being upfront about: 29 analysts land on a consensus Buy with an average target of $157.41, about 8.5% upside, but individual targets range from RBC's $123 (Sector Perform) to Morgan Stanley's $165 (Overweight), with Truist recently trimming to $150 and Barclays sitting at $145 (Equal Weight). That's a market genuinely split on how much credit to give the oncology and cell-therapy pivot before anito-cel actually clears its PDUFA date — which is exactly the kind of unresolved catalyst this note thinks is worth owning ahead of, not after.
12 What Could Go Wrong
- Biktarvy concentration is real and quantified: at roughly 49% of total revenue, any Medicare IRA negotiation outcome, competitive HIV entrant, or unexpected patent challenge would disproportionately impact the whole company.
- Anito-cel is not yet approved: the December 23, 2026 PDUFA date could bring a delay, a complete response letter, or label restrictions narrower than hoped, and manufacturing scale-up for a brand-new CAR-T construct carries genuine execution risk even with strong trial data already in hand.
- Cell therapy has already shown it can lose share quickly: Yescarta and Tecartus's 14% decline demonstrates this market rewards the newest, best-differentiated product aggressively — a dynamic that will apply to anito-cel eventually too, not just to Gilead's legacy products.
- Policy and pricing pressure is already showing up, not just theoretical: Gilead's own materials cite ACA and Medicaid pricing shifts causing a minor Q2 HIV market slowdown, and Medicare IRA negotiation risk on Biktarvy specifically is a named, ongoing exposure.
- Integrating three acquisitions simultaneously is a lot to execute on at once: Arcellx, Tubulis, and Ouro Medicines all closed in the same quarter, and management attention and integration bandwidth are finite even at a company Gilead's size.
- Veklury's decline is a real, ongoing revenue headwind: COVID treatment revenue fell 81% year over year and was guided down further for full-year 2026, a genuine drag the base-business growth numbers have to keep outrunning.
13 Muffett's Take
Gilead's headline Q2 loss was the kind of number that scares off investors who don't read past the first line, and we think that's exactly what created the opportunity here. Underneath the accounting noise sits a business growing its base revenue 10%, throwing off 87% gross margins on its core HIV franchise, crossing $1 billion in quarterly PrEP sales for the first time ever, and deploying that cash into a specific, well-structured $13 billion bet on rebuilding its oncology and cell-therapy future — including a genuinely differentiated CAR-T candidate with a firm approval date now less than four months away.
This isn't a stock we're recommending because it's cheap and broken. It's a stock we're recommending because it's a durable, dividend-paying, low-volatility compounder trading at a reasonable multiple, with a real near-term catalyst in anito-cel that the market's split analyst targets suggest isn't fully priced in either direction yet. That's a comfortable kind of uncertainty to own into.
